327 related articles for article (PubMed ID: 11024059)
21. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein.
Yu F; White SB; Zhao Q; Lee FS
Cancer Res; 2001 May; 61(10):4136-42. PubMed ID: 11358837
[TBL] [Abstract][Full Text] [Related]
22. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
[TBL] [Abstract][Full Text] [Related]
23. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
24. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
[TBL] [Abstract][Full Text] [Related]
25. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
26. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
27. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
28. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
30. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
Kamura T; Sato S; Iwai K; Czyzyk-Krzeska M; Conaway RC; Conaway JW
Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10430-5. PubMed ID: 10973499
[TBL] [Abstract][Full Text] [Related]
31. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
32. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
33. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
34. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.
Maranchie JK; Vasselli JR; Riss J; Bonifacino JS; Linehan WM; Klausner RD
Cancer Cell; 2002 Apr; 1(3):247-55. PubMed ID: 12086861
[TBL] [Abstract][Full Text] [Related]
35. The von Hippel-Lindau tumor suppressor gene product promotes, but is not essential for, NEDD8 conjugation to cullin-2.
Wada H; Yeh ET; Kamitani T
J Biol Chem; 1999 Dec; 274(50):36025-9. PubMed ID: 10585493
[TBL] [Abstract][Full Text] [Related]
36. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma.
Choi JW; Park SC; Kang GH; Liu JO; Youn HD
Cancer Res; 2004 Jan; 64(1):35-9. PubMed ID: 14729605
[TBL] [Abstract][Full Text] [Related]
37. VHL takes HIF's breath away.
Krek W
Nat Cell Biol; 2000 Jul; 2(7):E121-3. PubMed ID: 10878820
[TBL] [Abstract][Full Text] [Related]
38. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.
Schoenfeld AR; Davidowitz EJ; Burk RD
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8507-12. PubMed ID: 10900011
[TBL] [Abstract][Full Text] [Related]
39. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
40. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.
Yu F; White SB; Zhao Q; Lee FS
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9630-5. PubMed ID: 11504942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
